Patents Assigned to EDITAS MEDICINE, INC.
  • Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
    Patent number: 11512311
    Abstract: CRISPR/RNA-guided nuclease-related compositions and methods for treatment of A1AT deficiency and associated conditions are disclosed.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: November 29, 2022
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Shen Shen, Penrose O'Donnell, Minerva Sanchez
  • Methods and systems for analyzing guide RNA molecules
    Patent number: 11499151
    Abstract: The present disclosure relates to methods of assessing a sample of guide RNAs (gRNAs).
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: November 15, 2022
    Assignee: Editas Medicine, Inc.
    Inventors: Cecilia Fernandez, Georgia Giannoukos, Luis Barrera, Dawn Ciulla, Terence Ta
  • EVALUATION OF CAS9 MOLECULE/GUIDE RNA MOLECULE COMPLEXES
    Publication number: 20220325326
    Abstract: Disclosed herein are methods for evaluation, selection, optimization, and design of Cas9 molecule/gRNA molecule complexes.
    Type: Application
    Filed: November 22, 2021
    Publication date: October 13, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Hariharan JAYARAM, William SELLECK
  • COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASE
    Publication number: 20220273818
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: October 11, 2021
    Publication date: September 1, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
  • CRISPR/cas-related methods and compositions for treating herpes simplex virus
    Patent number: 11390861
    Abstract: Genome editing systems and genetic constructs that target a herpes simplex virus (HSV) viral gene, where the systems comprise one Cas9 molecule, and a gRNA molecule, compositions and cells comprising such genome editing systems and genetic constructs as well as methods for using the genome editing systems, genetic constructs, compositions and cells for genome engineering, and for preventing, treating or reducing HSV infection.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: July 19, 2022
    Assignees: EDITAS MEDICINE, INC., DUKE UNIVERSITY
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot, Bryan R. Cullen
  • CRISPR-related methods and compositions with governing gRNAS
    Patent number: 11390887
    Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: July 19, 2022
    Assignees: Editas Medicine, Inc., The Broad Institute Inc., Massachusetts Institute of Technology, University of Iowa Research Foundation
    Inventors: Feng Zhang, Deborah Palestrant, Beverly Davidson, Jordi Mata-Fink, Edgardo Rodriguez, Alexis Borisy
  • Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
    Patent number: 11390884
    Abstract: The methods and compositions described herein surprisingly increase CRISPR/Cas-mediated gene editing in stem cells by transiently treating the cells with a stem cell viability enhancer prior to and/or after contacting the cells with one or more CRISPR/Cas9 components. Further, this treatment also surprisingly results in increased engraftment of the stem cells into the target tissue of a subject. The present disclosure also provides one or more modified CRISPR/Cas9 components which, when used in combination with the stem cell viability enhancer, further increases the frequency of gene editing in stem cells, increases stem cell viability, and increases stem cell engraftment.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: July 19, 2022
    Assignee: Editas Medicine, Inc.
    Inventor: Jennifer Leah Gori
  • CELLS EXPRESSING A RECOMBINANT RECEPTOR FROM A MODIFIED TGFBR2 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS
    Publication number: 20220184131
    Abstract: Provided herein are engineered immune cells, e.g. T cells, expressing a recombinant receptor, that contain a modified transforming growth factor-beta receptor type-2 (TGFBR2) locus encoding the recombinant receptor or a portion thereof. In some aspects, the cells are engineered by targeted integration of a transgene sequence encoding the recombinant receptor or a portion thereof, at a TGFBR2 genomic locus. Also provided are cell compositions containing the engineered immune cells, nucleic acids for engineering cells, and methods, kits and articles of manufacture for producing the engineered cells, such as by targeting a transgene sequence encoding a recombinant receptor or a portion thereof for integration into a region of a TGFBR2 genomic locus. In some embodiments, the engineered cells, e.g. T cells, can be used in connection with cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered cells.
    Type: Application
    Filed: April 30, 2020
    Publication date: June 16, 2022
    Applicants: Juno Therapeutics, Inc., Editas Medicine, Inc.
    Inventors: Stephen Michael Burleigh, Cedric CLEYRAT, Melissa CHIN, Fred HARBINSKI, Christopher Heath NYE, Blythe D. SATHER, Queenie VONG, G. GRANT WELSTEAD, Christopher WILSON
  • Compositions and methods for treating CEP290-associated disease
    Patent number: 11339437
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: May 24, 2022
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee Maeder, Rina J. Mepani, David A. Bumcrot, Shen Shen, Michael Stefanidakis
  • MODIFIED NATURAL KILLER (NK) CELLS FOR IMMUNOTHERAPY
    Publication number: 20220143084
    Abstract: The present disclosure is directed to the generation of NK cells (or other lymphocytes) from induced pluripotent cells that have been derived from cells, e.g., developmentally mature T cells, and uses thereof for immunotherapy.
    Type: Application
    Filed: February 14, 2020
    Publication date: May 12, 2022
    Applicant: Editas Medicine, Inc.
    Inventors: Gordon Grant Welstead, Christopher Borges, Karrie Ka Wai Wong
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA
    Publication number: 20220135970
    Abstract: CRISPR/Cas-related compositions and methods for treatment of Usher Syndrome and/or Retinitis Pigmentosa are disclosed herein.
    Type: Application
    Filed: June 7, 2021
    Publication date: May 5, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan L. MAEDER, David A. BUMCROT
  • CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP)
    Publication number: 20220133768
    Abstract: CRISPR/RNA-guided nuclease-related compositions and methods for treatment of RHO-associated retinitis pigmentosa, e.g., autosomal-dominant retinitis pigmentosa (adRP).
    Type: Application
    Filed: February 25, 2020
    Publication date: May 5, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Benjamin Aryeh DINER, Deepak REYON
  • CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)
    Patent number: 11268086
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: March 8, 2022
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee Maeder, David A. Bumcrot, Shen Shen
  • SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20220047637
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.
    Type: Application
    Filed: November 27, 2019
    Publication date: February 17, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Edouard AUPEPIN DE LAMOTHE-DREUZY, KaiHsin CHANG, Jack HEATH
  • CRISPR/CAS-related methods and compositions for treating sickle cell disease
    Patent number: 11242525
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Sickle Cell Disease (SCD) are disclosed.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: February 8, 2022
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Morgan L. Maeder, G. Grant Welstead, David A. Bumcrot
  • Cas9 fusion molecules, gene editing systems, and methods of use thereof
    Patent number: 11236313
    Abstract: Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 1, 2022
    Assignee: Editas Medicine, Inc.
    Inventors: Cecilia Cotta-Ramusino, Hariharan Jayaram, John Anthony Zuris
  • SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20220025363
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.
    Type: Application
    Filed: December 8, 2020
    Publication date: January 27, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Jennifier Leah GORI, Edouard AUPEPIN DE LAMOTHE-DREUZY, Jack HEATH, John Anthony ZURIS, KaiHsin CHANG
  • SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA
    Publication number: 20220017927
    Abstract: Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.
    Type: Application
    Filed: May 27, 2021
    Publication date: January 20, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Hariharan Jayaram, Barrett Ethan Steinberg
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS
    Publication number: 20220010313
    Abstract: CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.
    Type: Application
    Filed: April 19, 2021
    Publication date: January 13, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
    Publication number: 20210380987
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Cystic Fibrosis (CF).
    Type: Application
    Filed: April 30, 2021
    Publication date: December 9, 2021
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Deepak Reyon, Morgan L. Maeder, Ari E. Friedland, G. Grant Welstead, David A. Bumcrot